GlassScriptPhysician profile
Eve D Charasz
NPI 1558397539
$16,171.86
in general payments reported to CMS, 2019-2025
25 companies · $1,963 in 2025
The $1,963 reported for 2025 was more than what 97% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,718 · 2020: $1,554 · 2021: $2,013 · 2022: $2,544 · 2023: $2,427 · 2024: $1,952 · 2025: $1,963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,341.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,212.52 | 2019-2025 | Evenity, Krystexxa, Repatha |
| Abbvie INC. | $2,020.56 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,334.49 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Teva Pharmaceuticals USA, INC. | $1,329.81 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $1,245.30 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $1,097.08 | 2019-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $1,003.17 | 2021-2023 | Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $955.10 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $562.20 | 2019-2025 | Mounjaro, Jardiance |
| Esperion Therapeutics, INC. | $494.45 | 2021 | |
| Amarin Pharma, INC. | $490.09 | 2019-2025 | Vascepa |
| Pfizer INC. | $430.47 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $364.77 | 2020-2025 | |
| Lundbeck LLC | $278.81 | 2023-2025 | Vyepti, Rexulti |
| Genzyme Corporation | $216.77 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $202.06 | 2019 | |
| Abbott Laboratories | $188.41 | 2022-2023 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $132.02 | 2022 | |
| Daiichi Sankyo INC. | $123.82 | 2024 | Injectafer |
| Allergan, INC. | $111.36 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.01 | 2019 | |
| Comsort, INC | $100.00 | 2019 | |
| Boston Scientific Corporation | $95.46 | 2025 | General - Pain Management, Intracept |
| Acelrx Pharmaceuticals, INC. | $58.12 | 2020 | |
| Rayner Intraocular Lenses Limited | $25.01 | 2025 | Omidria |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eve Charasz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.